ESSA Pharma (EPIX) Proxy Filing summary

Executive summary

• Annual general meeting scheduled for March 5, 2025, to address key governance and business matters.

• Shareholders will vote on setting the number of directors, electing directors, executive compensation, and auditor appointment.

• Proxy materials are distributed primarily via internet access, with paper copies available upon request.

• Shareholders of record as of January 8, 2025, are eligible to vote and attend.

Voting matters and shareholder proposals

• Proposals include setting the number of directors at seven, electing seven directors, advisory vote on executive compensation, and appointment of Davidson & Company LLP as auditor.

• Board recommends voting “FOR” all proposals.

• Shareholder proposals for the 2026 meeting must be submitted by September 30, 2025.

• Advance notice policy governs director nominations by shareholders.

Board of directors and corporate governance

• Board currently has ten directors, with seven nominees proposed for the next term.

• Nine of ten current directors are independent; separation of Chair and CEO roles is maintained.

• Board committees include audit, compensation, and corporate governance/nomination, each with independent chairs.

• Board diversity policy in place; 20% of directors and 25% of executive officers are female.

• Overboarding policy limits non-CEO directors to five public company boards.